Table 4.
Peak Fever Height and Adverse Reactions Upon Fever Induction
| Temperature and Side Effects | Group A1 Bacterial Extracts, No Preceding Hyperthermia, 135 Applications |
Group A2 Bacterial Extracts, Preceding Whole Body Hyperthermia, 215 Applications |
Group B Combinations of Approved Drugs, Preceding Whole-Body Hyperthermia, 100 Applications |
|---|---|---|---|
| Peak body temperature (oC±SD) | Ps 39,1 ± 0,71 Se 39,2 ± 0,81 |
Ps 39,2 ± 0,67 Se 39,4 ± 0,78 |
39,6 ± 0.86 |
| Nausea/vomitting (%) | Ps 15, Se 24,9 |
Ps 6,1 Se 8,2 |
26 |
| Headache (%) | Ps 12, Se 19,3 |
Ps 5,5 Se 6,1 |
25 |
| Back pain (%) | Ps 5,4 Se 7,4 |
Ps 2,4 Se 2,3 |
12 |
| Circulatory reactions (%) | Ps 7,7 Se 10,9 |
Ps 3,1 Se 3,2 |
0,5 |
| Weakness next day (%) | Ps 17,7 Se 21,2 |
Ps 13,1 Se 16,1 |
0,5 |
Group A1: application of bacterial extracts (Se: Serratia marcescens+Streptococcus pyogenes, Ps: Pseudomonas aeruginosa+Streptococcus pyogenes) without preceding hyperthermia. Group A2: application of bacterial extracts preceded by 30min whole body hyperthermia. Group B: application of combinations of approved drugs (Colibiogen, Iscador, Picibanil, Polyvaccinum forte, Strovac) usually preceded by whole body hyperthermia (intermittend single drug applications of bacterial extracts excluded).